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EDITORIAL COMMENT
G Protein-Coupled
Receptor Kinases: Gotta
Real Kure for Heart Failure?*
Susan F. Steinberg, MD
New York, New York
With over five million patients in the U.S. alone carrying
the diagnosis of chronic congestive heart failure, innovative
treatments to delay its progression and/or ameliorate its
symptoms remain a high priority of cardiovascular research.
The G protein-coupled receptors (GPCRs) for cat-
echolamines remain a centerpiece of heart failure research.
As a result of research in several laboratories, the traditional
notion that catecholamine actions are mediated by the
predominant b1-adrenergic receptor (b1-AR) subtype has
been broadened to encompass a b2-AR component, which
also provides inotropic support and influences cardiomyo-
cyte cell biology (particularly in the failing or aged myocar-
dium where there is selective downregulation of b1-ARs).
For both b1- and b2-ARs, activation involves a conforma-
tional change that facilitates interactions with stimulatory
heterotrimeric Gs proteins, leading to activation of adenylyl
cyclase and formation of cyclic adenosine monophosphate
(cAMP). However, recent studies identify differences in the
pathways for b1- versus b2-AR activation of adenylyl
cyclase, b-AR subtype actions that go beyond the genera-
tion of cAMP, and effects of b-ARs on cardiomyocyte gene
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expression, growth and survival ([1], and references cited
therein). The distinct signaling properties of bg dimers
(liberated with guanosine triphosphate [GTP]-bound alpha
subunits upon heterotrimeric G protein activation) also
explain some of the complexities in b-AR subtype signaling.
One target of bg dimers that has received considerable
recent attention is the G protein-coupled receptor kinases
(GRKs) that phosphorylate agonist-activated GPCRs.
Therapies targeted to b-ARs are cornerstones of heart
failure management, despite lingering controversies regard-
ing the role of b-AR signaling in the pathogenesis of heart
failure. Traditionally, b-ARs were viewed as providing
essential inotropic support for the failing heart. However,
the evidence that chronic b-AR signaling leads to long-
term adverse effects that accelerate the natural history of
heart failure (offsetting any short-term benefit) has raised
serious questions regarding the optimal therapeutic ap-
proach to the b-AR desensitization that develops in re-
sponse to the chronically enhanced sympathetic tone of
heart failure. Some investigators cite clinical evidence that
long-term b-AR blockade reduces the combined risk of
morbidity and mortality in heart failure as support for the
notion that depressed b-AR signaling in heart failure is
cardioprotective (2). According to this formulation, b-AR
activation contributes to the progression of heart failure;
pharmacologic strategies to interfere with b-AR signaling
provide clinical benefit.
However, other investigators emphasize evidence that
strategies designed to increase b2-AR activity or reverse
b-AR desensitization (by reducing GRK levels) are well
tolerated, improve myocardial performance and prolong
survival in experimental models of heart failure. These
results are taken in support of the diametrically opposite
view that the depressed b-AR response (and the GRKs that
desensitize b-ARs) constitute a convenient target for ther-
apeutic intervention in heart failure. In this context, the
study by Iaccarino et al. (3) in this issue of the Journal
focuses specifically on the role of GRK2 (one GRK family
member) in the pathogenesis of impaired b-AR responsive-
ness and cardiac failure that develops when transgenic mice
that overexpress wild-type a1B-ARs (Tga43) are subjected
to treatment with phenylephrine (PE) (3). The study
confirms a previous observation that b-AR activation of
adenylyl cyclase is impaired in Tga43 mice (4). In the
previous study (4), this was attributed to heightened GRK
activity, which develops—without any detectable change in
GRK2 protein expression—in the compensated hypertro-
phy displayed by Tga43 mice (3,4). Phenylephrine induces
moderate cardiac hypertrophy, with few biochemical abnor-
malities, in nontransgenic littermates. However, PE elicits a
severe “maladaptive” hypertrophy with progressive bio-
chemical markers of cardiac failure (impaired b-AR signal-
ing, elevated GRK2 expression) and reduced survival in
Tga43 mice. Reduced cardiac neuropeptide Y stores in
PE-treated Tga43 mice is interpreted as evidence for
chronic sympathetic nervous system activation, which is
implicated in the induction of GRK2 expression. The
investigators suggest that increased GRK2 expression con-
tributes to the evolution of heart failure in this model. Given
the growing enthusiasm for GRKs as a potential novel
target for heart failure therapy, the comments that follow
briefly review its structure and the elaborate/interconnecting
networks of regulatory signals recently shown to influence
its function. The aim is to evaluate critically the experimen-
tal basis for current concepts regarding the role of GRK2 in
the evolution of cardiac dysfunction and consider potential
long-term consequences of GRK2 inhibition.
The GRKs have emerged as a family of six members that
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specifically phosphorylate GPCRs, but only following ago-
nist activation (homologous desensitization). The overall
topology of GRKs is characterized by a somewhat conserved
central catalytic domain flanked by C- and N-terminal
regulatory sequences ([5,6] and references cited therein).
The GRKs are classified into three categories, based upon
divergence in their C-terminal domain architecture and
membrane-targeting mechanisms. These comments are
confined to the three GRKs (GRK2 [bARK1], GRK3
[bARK2], and GRK5) that fall into two subclasses and are
the most abundant isoforms expressed by cardiomyocytes.
Both GRK2 and its structural homologue GRK3 are pri-
marily cytosolic in resting cells; they become targeted to the
membrane as a result of an interaction between their
C-terminal pleckstrin-homology domains, membrane PIP2,
and membrane-anchored G protein bg dimers.
Recent studies identified sequence homology between the
N-terminus of GRK2 or GRK3 and regulators of G protein
signaling (RGS) family proteins, proteins that serve as
GTPase-activating proteins (GAP) by binding to the tran-
sition state of Ga subunits and accelerating their intrinsic
rates of GTP hydrolysis (i.e., limiting their half-lives of
activation). Indeed, the N-terminus of GRK2 or GRK3
binds tightly to Gaq/11 proteins (but not Gai, Ga12/13 or
Gas). However, GRK2 and GRK3 display only weak GAP
activity for Gaq (relative to RGS proteins); Gq inhibition is
due to the sequestration of active Gaq subunits (7,8).
Hence, GRK2 and GRK3 exert multidomain regulation of
GPCR signaling; phosphorylation of agonist-occupied
GPCRs by the catalytic domain leads to homologous
desensitization, whereas phosphorylation-independent
binding interactions inhibit the bifurcating Gq signaling
pathway by sequestering Gaq subunits (GRK C-terminus)
and Gbg dimers (GRK N-terminus).
Despite their high degree of structural homology, GRK2
and GRK3 display unanticipated in vivo specificity toward
certain GPCRs. For example, GRK2 desensitizes b-ARs
and angiotensin II type 1A receptors, whereas GRK3 does
not (6). Conversely, GRK3 (but not GRK2) desensitizes
a1B-ARs and protease-activated receptor-1 (PAR-1, the
receptor for thrombin and other proteases, which elevates
calcium and promotes cardiomyocyte hypertrophy [6,9–
11]). The structural basis for differences in GRK2 and
GRK3 substrate specificity has been mapped to a region of
substantial sequence divergence in their Gbg-binding do-
mains (the region critical for GRK-Gbg interactions). This
suggests a model wherein specificity in GPCR–GRK inter-
actions is dictated by the distinct pools of structurally
distinguishable Gbg dimers released by various GPCRs
that recruit different GRK isoforms to the plasma mem-
brane.
Cardiomyocytes also express the structurally distinct
GRK5 enzyme that phosphorylates agonist-occupied
GPCRs, but does not bind Gaq/11 proteins and does not
require membrane translocation for activation; it is consti-
tutively membrane-anchored through a cluster of positively
charged residues located at the C-terminus. The GRK5
desensitizes b1-ARs, PAR-1 and (to a lesser extent) a1B-
ARs, but not angiotensin II receptors (6).
Recent studies identify an inhibitory interaction between
the N-termini of GRK2 and GRK5 and caveolin, the
structural protein that drives formation of caveolae mem-
brane subdomains (12). The evidence that caveolin expres-
sion is highly regulated, and reportedly decreases during
chronic b-AR stimulation (as occurs in heart failure [13]),
has fueled speculation that this interaction might influence
b-AR signaling. According to this formulation, decreased
inhibitory caveolin provides an ancillary mechanism to
elevate GRK and impair b-AR responsiveness in heart
failure, as the bulk of the cardiomyocyte b-ARs reside in
caveolae (12,14).
The GRK-dependent phosphorylation of agonist-
occupied GPCRs facilitates the binding of b-arrestin,
which sterically hinders the interaction between agonist-
occupied GPCRs and their cognate G proteins, thereby
initiating agonist-induced receptor desensitization and in-
ternalization. Also, b-arrestins function as adapter proteins
to promote the stable association of other molecules with
GPCRs. The b-arrestin docks Src tyrosine kinase, an
upstream element in ERK and JNK cascades, and com-
ponents of the endocytic machinery (AP-2, clathrin). In this
manner, b-arrestin plays a role in GPCR trafficking,
desensitization/resensitization, and initiates a “second-
wave” of effector responses. The contribution of b-arrestin
binding to ERK/JNK activation by GPCRs has received
intense recent scrutiny in heterologous expression systems. In
theory, b-arrestin binding should carry similar significance for
GPCR (and b-AR) signaling in cardiomyocytes. However,
given ample evidence for the contextual nature of GPCR
signaling (with differences in the molecular machinery
between cells markedly influencing GPCR signaling phe-
notype), any conclusions regarding the importance of this
mechanism in the heart await specific experimental valida-
tion.
With these comments as background, the following
questions consider the role of GRKs in cardiac failure: Does
an increase in GRK2 expression provide a generalized mecha-
nism to explain reduced cardiac b-AR responsiveness; is it a
general marker of cardiac hypertrophy? A potential role for
GRK2 in the regulation of b-AR sensitivity was first
suggested based upon evidence that steady-state levels of
GRK2 mRNA are elevated in a wide range of human and
animal models of cardiac dysfunction, where b-AR activa-
tion of adenylyl cyclase and modulation of contractile
function is impaired (reviewed in [6]). However, impaired
b-AR responsiveness without a detectable change in GRK2
expression is reported in some syndromes of cardiac hyper-
trophy/dysfunction (e.g., mice that overexpress Gaq pro-
teins or the constitutively active a1B-AR mutant [6,15]).
The GRK5 rather than GRK2 is elevated in tachycardia-
induced heart failure in pigs (16). Cardiac b1-AR and
b2-AR responsiveness is reduced, without any change in
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steady-state GRK2 or GRK5 mRNA levels or GRK activ-
ity, during normal aging of the rat ventricle (17).
The prevailing evidence from the current study by Iac-
carino et al. (3) as well as previous studies (5,6) is that
increased GRK expression results from the enhanced sym-
pathetic nervous system activity in heart failure. Increased
GRK expression is not detected in models of cardiac
hypertrophy that bypass the b-AR signaling pathway (hy-
pertrophy induced by a1-ARs, Gaq, or Ras); it is not a
requisite feature of hypertrophy itself. This is most convinc-
ingly demonstrated by a previous study showing that iso-
proterenol infusion leads to cardiac hypertrophy with in-
creased GRK2 mRNA, protein, and activity; PE infusion,
at a concentration that induces a similar degree of hyper-
trophy, does not alter GRK2 expression (6).
Are changes in GRK in heart failure optimally detected as
changes in mRNA/protein expression or enzyme activity? In
the studies cited above, disease-dependent alterations were
monitored as changes in GRK expression or activity (vari-
ably both). The precise method used to detect disease-
dependent changes in GRK may be pertinent, as recent
studies identify distinct mechanisms that regulate GRK
expression and activity. The observation that a1B-AR acti-
vation rapidly translocates GRK2 to the plasma membrane
provided the first evidence that GRK2 function can increase
as a result of enhanced activity, without induction of GRK2
protein/mRNA expression. Subsequent studies identified
specific regulation of GRKs by protein kinase-C (PKC) and
calcium. The PKC phosphorylation increases GRK2, but
decreases GRK5, activity (5,6). The GRK5 (and to a lesser
extent GRK2) activity is inhibited by calcium as a result of
an interaction between its N-terminal regulatory domain
and the calcium-binding protein calmodulin. However,
PKC-dependent phosphorylation of GRK2 relieves
calmodulin-dependent inhibition of GRK2 (18). Hence,
signaling by a1-ARs tends to favor GRK2 activation (while
turning off GRK5). This mechanism might explain the
increased GRK activity (without an increase in GRK
protein expression) that is reported to impair b-AR respon-
siveness in Tga43 mice. The predicted consequences of
activation of the a1-AR/PKC pathway include decreased
signaling by b-ARs (which are regulated by GRK2 and
GRK5), decreased signaling by angiotensin II type 1A
receptors (which are regulated by GRK2, but not GRK5),
but persistent signaling by PAR-1 (which is regulated by
GRK5, but not GRK2). These newer concepts regarding
GRK regulation would effectively implicate GRK more
broadly in the impaired b-AR responsiveness that develops
in various experimental models of cardiac hypertrophy
(including potentially in the Gaq and a1B-AR overexpress-
ing mice, where b-AR responsiveness is impaired without
an increase in GRK2 expression). However, these newer
studies also introduce a fundamental uncertainty regarding
the role of GRK in the pathogenesis of heart failure.
Iaccarino et al. (3) in the current study suggest that
increased GRK2 expression is key for the transition from
myocardial hypertrophy to cardiac failure. Does the en-
hanced GRK activity in TGa43 mice with stable, compen-
sated hypertrophy hold similar significance?
Current published reports focus on elevated GRK as the
mechanism for impaired b-AR responsiveness in heart
failure, but Serikov et al. (19) recently demonstrated that
lowering extracellular calcium to relieve the calcium load
restores b-AR responsiveness in several transgenic murine
models of hypertrophy and heart failure. These investigators
speculate that b-AR responsiveness is impaired in cardiac
failure as a result of an alternative mechanism involving
calcium-dependent inhibition of cardiac adenylyl cyclase
isoforms (19). The relative importance of GRK versus
calcium overload must be considered in future studies.
Does increased GRK2 contribute to myocardial dysfunction
and the pathogenesis of heart failure? Current studies provide
ample support for the conclusion that GRK regulates
signaling by b-ARs (and other GPCRs). However, the
more generalized conclusion that GRKs play a key role in
the pathogenesis of cardiac failure is less certain. The most
convincing evidence to implicate GRKs in heart failure
comes from studies in the genetic murine dilated cardiomy-
opathy caused by ablation of the muscle LIM protein. Here,
GRK2 expression and activity are elevated. Inhibition of
GRK, by crossing with mice that overexpress bARKct (a
peptide that contains the Gbg binding domain and com-
petes with endogenous GRK for binding and Gbg-
mediated translocation to the membrane), prevents the
development of heart failure (6). However, in other models
of hypertrophy, GRKs are reported to restore b-AR respon-
siveness and inotropic reserve, without preventing the de-
velopment of hypertrophy (5,6,20). Inhibition of GRK
(with bARKct) has no effect on the impaired b-AR
responsiveness (or hypertrophy) that develops in mice that
overexpress Gaq (which do not display increased GRK
[21]). Finally, in pacing-induced heart failure in pigs,
GRK5 expression is increased and b-AR signaling is im-
paired to a similar degree in the functionally normal
ventricle and in regions of the ventricle that display in-
creased wall thickness and abnormal contractility (16).
Collectively, these results suggest that GRK is neither a
requisite mediator of hypertrophy nor necessarily a precise
predictor of the contractile state of the cardiomyocyte.
Do changes in GRK expression influence b-AR signaling to
growth regulatory pathways? Studies to date have focused on
GRK desensitization of pathways leading to cAMP accu-
mulation and inotropic support. However, ample evidence
shows that individual b-AR subtypes differ in their coupling
to this and other signaling mechanisms that contribute to
the pathogenesis of hypertrophy and the transition to
cardiac failure. The most striking evidence for complex
regulatory actions of b-AR subtypes comes from studies in
transgenic mice, where b2-ARs increase adenylyl cyclase
activity and elevate contractile function without obvious
evidence of cardiotoxicity (unless b2-AR expression is
forced to very high levels or maintained for protracted
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intervals). In marked contrast to the relatively wide “thera-
peutic window” for b2-AR overexpression (6,22), even low
levels of transgenic b1-AR overexpression rapidly lead to a
dilated cardiomyopathy with fibrosis and cardiomyocyte
apoptosis (6). These results emphasize the very distinct
cellular actions of b1-versus b2-ARs.
The signaling properties of individual b-AR subtypes
have been deciphered largely in cardiomyocyte cultures,
where b-AR activation induces morphologic and molecular
features of hypertrophy (23). In initial studies, the anabolic
response was attributed to b-AR activation of the ERK
cascade via pathways that involve both Gs/cAMP/PKA and
Gi protein bg dimers/Src/Ras/Raf/ERK. An elaborate
mechanism involving PKA-dependent phosphorylation of
b-ARs, which switches b-AR coupling from Gs to Gi, and
leads to ERK activation by a bg dimer pathway, was
proposed ([24] and references cited therein). The implicit
assumption of these studies was that ERK activation is
mediated by b2-ARs (PKA-dependent modulation of
G-protein-coupling preference has only been shown for
b2-ARs). However, other studies place ERK downstream
from both b1- and b2-AR subtypes (25,26), and two recent
studies implicate b1-ARs in cardiomyocyte hypertrophy
(27,28). Hence, other mechanisms, including a pathway
initiated by GRK-dependent phosphorylation of b-ARs,
which facilitates b-arrestin binding as a scaffold for ERK
activation also must be considered in future studies.
Consistent with the marked cardiotoxic properties of
b1-ARs (relative to b2-ARs) in transgenic mice, other
studies identify an effect of b1-ARs to induce cardiomyocyte
apoptosis (28) and an effect of b2-ARs to counter the
pro-apoptotic actions of b1-AR via a Gi-dependent path-
way involving phosphoinositide 39-kinase/AKT (and not
ERK [24]). Recent studies also identify b-AR activation of
calcineurin (via a calcium-dependent pathway) and Src
family protein tyrosine kinases (via direct cAMP-
independent actions of Gas subunits); both of these mole-
cules have been implicated in the induction of hypertrophy
and apoptosis (29,30). Hence, many different effectors
(some with opposing actions) have been implicated as
downstream targets for b1- and b2-ARs, at least in model
systems. Physiologic responses to b-ARs in the intact heart
will be defined by the balance of signaling through these
highly integrated molecular signals. Current knowledge
provides little guidance to predict whether GRK-dependent
desensitization of cAMP responses is accompanied by a
global loss of b-AR signals. For example, increased GRK2-
dependent phosphorylation of GPCRs (b-ARs or others)
might actually facilitate arrestin binding and signaling via
the ERK pathway. A previous observation that cardiomyo-
cytes isolated from ventricles of mice that overexpress
GRK2 display increased resting cell length (relative to
wild-type controls [6]) would be consistent with the notion
that increased GRK2 contributes to the acquisition of
certain morphological features of hypertrophy; however,
more direct studies are required.
Finally, current published reports focus largely on GRK
regulation of b-AR signaling to adenylyl cyclase. The
challenge of future studies will be to broaden the analysis to
consider the role of GRKs in signaling by individual b-AR
subtypes to effectors that are predicted to influence cardio-
myocyte structure, gene expression, and survival during
hypoxic insults (MAPK cascades, the PI-3K/AKT pathway,
Src). These trophic effects of b-ARs ultimately are likely to
be as important as cAMP in determining the relative
contribution of b-AR activation to the progression of heart
failure and/or survival.
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